Cargando…
Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study
The efficacy of intravenous immunoglobulins (IVIg) in patients with autoimmune diseases (AID) has been known for several decades. Majority of these patients received IVIg in hospital. A retrospective study was conducted in 22 centers in France to evaluate the feasibility of the administration of Teg...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875056/ https://www.ncbi.nlm.nih.gov/pubmed/29736397 http://dx.doi.org/10.1155/2018/8147251 |
_version_ | 1783310292313178112 |
---|---|
author | Hachulla, Eric Le Masson, Gwendal Solé, Guilhem Hamidou, Mohamed Desnuelle, Claude Azulay, Jean-Philippe Besson, Gérard Swiader, Laure Abad, Sébastien Antoine, Jean-Christophe Bouhour, Françoise Créange, Alain Grenouillet, Marike Magy, Laurent Marcel, Sébastien Paquet, Jean-Michel Rouhart, François Ziegler, François Mathis, Stéphane Gauthier-Darnis, Marc Puget, Sophie |
author_facet | Hachulla, Eric Le Masson, Gwendal Solé, Guilhem Hamidou, Mohamed Desnuelle, Claude Azulay, Jean-Philippe Besson, Gérard Swiader, Laure Abad, Sébastien Antoine, Jean-Christophe Bouhour, Françoise Créange, Alain Grenouillet, Marike Magy, Laurent Marcel, Sébastien Paquet, Jean-Michel Rouhart, François Ziegler, François Mathis, Stéphane Gauthier-Darnis, Marc Puget, Sophie |
author_sort | Hachulla, Eric |
collection | PubMed |
description | The efficacy of intravenous immunoglobulins (IVIg) in patients with autoimmune diseases (AID) has been known for several decades. Majority of these patients received IVIg in hospital. A retrospective study was conducted in 22 centers in France to evaluate the feasibility of the administration of Tegeline, an IVIg from LFB Biomedicaments, and assess its safety at home, compared to in hospital, in patients with AID. The included patients were at least 18 years old, suffering from AID, and treated with at least 1 cycle of Tegeline at home after receiving 3 consecutive cycles of hospital-based treatment with Tegeline at a dose between 1 and 2 g/kg/cycle. Forty-six patients with AID, in most cases immune-mediated neuropathies, received a total of 138 cycles of Tegeline in hospital and then 323 at home. Forty-five drug-related adverse events occurred in 17 patients who received their cycles at home compared to 24 adverse events in hospital in 15 patients. Serious adverse events occurred in 3 patients during home treatment, but they were not life-threatening and did not lead to discontinuation of Tegeline. Forty-five patients continued their treatment with Tegeline at home or in hospital; 39 (84.8%) were still receiving home treatment at the end of the study. In conclusion, the study demonstrates the good safety profile of Tegeline administered at home at high doses in patients with AID who are eligible for home administration of Tegeline. |
format | Online Article Text |
id | pubmed-5875056 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-58750562018-05-07 Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study Hachulla, Eric Le Masson, Gwendal Solé, Guilhem Hamidou, Mohamed Desnuelle, Claude Azulay, Jean-Philippe Besson, Gérard Swiader, Laure Abad, Sébastien Antoine, Jean-Christophe Bouhour, Françoise Créange, Alain Grenouillet, Marike Magy, Laurent Marcel, Sébastien Paquet, Jean-Michel Rouhart, François Ziegler, François Mathis, Stéphane Gauthier-Darnis, Marc Puget, Sophie Biomed Res Int Research Article The efficacy of intravenous immunoglobulins (IVIg) in patients with autoimmune diseases (AID) has been known for several decades. Majority of these patients received IVIg in hospital. A retrospective study was conducted in 22 centers in France to evaluate the feasibility of the administration of Tegeline, an IVIg from LFB Biomedicaments, and assess its safety at home, compared to in hospital, in patients with AID. The included patients were at least 18 years old, suffering from AID, and treated with at least 1 cycle of Tegeline at home after receiving 3 consecutive cycles of hospital-based treatment with Tegeline at a dose between 1 and 2 g/kg/cycle. Forty-six patients with AID, in most cases immune-mediated neuropathies, received a total of 138 cycles of Tegeline in hospital and then 323 at home. Forty-five drug-related adverse events occurred in 17 patients who received their cycles at home compared to 24 adverse events in hospital in 15 patients. Serious adverse events occurred in 3 patients during home treatment, but they were not life-threatening and did not lead to discontinuation of Tegeline. Forty-five patients continued their treatment with Tegeline at home or in hospital; 39 (84.8%) were still receiving home treatment at the end of the study. In conclusion, the study demonstrates the good safety profile of Tegeline administered at home at high doses in patients with AID who are eligible for home administration of Tegeline. Hindawi 2018-03-15 /pmc/articles/PMC5875056/ /pubmed/29736397 http://dx.doi.org/10.1155/2018/8147251 Text en Copyright © 2018 Eric Hachulla et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Hachulla, Eric Le Masson, Gwendal Solé, Guilhem Hamidou, Mohamed Desnuelle, Claude Azulay, Jean-Philippe Besson, Gérard Swiader, Laure Abad, Sébastien Antoine, Jean-Christophe Bouhour, Françoise Créange, Alain Grenouillet, Marike Magy, Laurent Marcel, Sébastien Paquet, Jean-Michel Rouhart, François Ziegler, François Mathis, Stéphane Gauthier-Darnis, Marc Puget, Sophie Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study |
title | Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study |
title_full | Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study |
title_fullStr | Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study |
title_full_unstemmed | Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study |
title_short | Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study |
title_sort | safety of intravenous immunoglobulin (tegeline®), administered at home in patients with autoimmune disease: results of a french study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875056/ https://www.ncbi.nlm.nih.gov/pubmed/29736397 http://dx.doi.org/10.1155/2018/8147251 |
work_keys_str_mv | AT hachullaeric safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT lemassongwendal safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT soleguilhem safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT hamidoumohamed safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT desnuelleclaude safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT azulayjeanphilippe safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT bessongerard safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT swiaderlaure safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT abadsebastien safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT antoinejeanchristophe safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT bouhourfrancoise safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT creangealain safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT grenouilletmarike safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT magylaurent safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT marcelsebastien safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT paquetjeanmichel safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT rouhartfrancois safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT zieglerfrancois safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT mathisstephane safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT gauthierdarnismarc safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy AT pugetsophie safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy |